Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells 23,429 Shares of Stock

Key Points

• CEO Fred Aslan sold 23,429 Artiva Biotherapeutics shares at an average price of $10.92, generating approximately $255,845. He retained 1.45 million shares, with the sale reducing his ownership by 1.59%.
• Artiva shares fell 0.8% to $10.79, while the company reported a quarterly loss of $0.63 per share, in line with analyst expectations. Analysts expect a full-year loss of $2.62 per share.
• Wall Street maintains a cautiously positive view, with a consensus “Moderate Buy” rating and a $39 price target, despite ratings ranging from Sell to Strong Buy.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $10.92, for a total value of $255,844.68. Following the completion of the transaction, the chief executive officer owned 1,449,765 shares of the company's stock, valued at $15,831,433.80. This trade represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Artiva Biotherapeutics Stock Down 0.8%

Shares of NASDAQ:ARTV traded down $0.09 during trading on Wednesday, hitting $10.79. 325,035 shares of the company traded hands, compared to its average volume of 375,371. Artiva Biotherapeutics, Inc. has a one year low of $2.22 and a one year high of $14.53. The business's fifty day moving average is $10.62 and its 200-day moving average is $8.88. The stock has a market capitalization of $527.52 million, a price-to-earnings ratio of -3.27 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.63). On average, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of large investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth $79,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics during the 2nd quarter worth approximately $58,000. Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics during the second quarter worth about $67,000. Bridgeway Capital Management LLC bought a new position in Artiva Biotherapeutics during the 2nd quarter valued at $53,000. Finally, BNP Paribas Financial Markets lifted its holdings in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock worth $340,000 after acquiring an additional 117,733 shares during the period.

Wall Street Analyst Weigh In

ARTV has been the topic of several recent research reports. Wall Street Zen raised shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Weiss Ratings reissued a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, Needham & Company LLC restated a "buy" rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.